99 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease.
Wichita State University
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine.
University of Oxford
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
Shionogi
In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
Shanghai Institute of Materia Medica
Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL
Shanghai University of Traditional Chinese Medicine
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
The University of Arizona
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
China Pharmaceutical University
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Shandong University
The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities.
Niddk
Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19.
Experimental Drug Development Centre
Bisubstrate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase.
University of Minnesota
Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
University of Colorado
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
Australian National University
The Natural Products Withaferin A and Withanone from the Medicinal Herb
Shiv Nadar University
A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir.
Experimental Drug Development Centre
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir.
Texas A&M University
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
Peking University
The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
Nankai University
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
The State University of New Jersey
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
University of Naples "Federico Ii
Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.
Eberhard Karls University T£Bingen
Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity.
University of Perugia
Target-Based Virtual Screening and LC/MS-Guided Isolation Procedure for Identifying Phloroglucinol-Terpenoid Inhibitors of SARS-CoV-2.
Kunming Institute of Botany
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Eberhard Karls University T£Bingen
Chemo- and Site-Selective Lysine Modification of Peptides and Proteins under Native Conditions Using the Water-Soluble Zolinium.
Chinese Academy of Sciences
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.
University of Alberta Edmonton
Oral Nonpeptidic, Noncovalent Triazine Coronavirus Main Protease Inhibitors for Treating COVID-19.
Experimental Drug Development Centre
Tuaimenal A, a Meroterpene from the Irish Deep-Sea Soft Coral
University of South Florida
Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases.
Heidelberg University
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
Texas A&M University
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
Texas A&M University
Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.
New York University Abu Dhabi
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
Kyushu University
Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.
Bio-Techne (Tocris)
Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
Mazandaran University of Medical Sciences
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.
Shandong University
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
University of California San Diego
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Jadavpur University
Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.
Chinese Academy of Medical Science and Peking Union Medical College
Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases.
Bristol University